U.S. Electronic Equipment and Components Stock News

Perfect (PERF) has put up a mixed Q2 2026 scorecard, with revenue of US$16.3 million, basic EPS of US$0.013 and net income of US$1.3 million. This may prompt investors to reassess the story around growth and profitability. Over the last six reported quarters, the company has seen quarterly revenue range between about US$16.0 million and US$18.7 million, while basic EPS has moved between roughly US$0.0006 and US$0.023, offering a broad view of how earnings have tracked against a relatively...

Citizens Community Bancorp (CZWI) just posted Q2 2026 results with total revenue of US$11.8 million and basic EPS of US$0.11, alongside trailing twelve month revenue of US$58.3 million and EPS of US$1.31. Over recent quarters the company has seen revenue move from US$14.8 million in Q2 2025 to US$15.6 million in Q4 2025 and US$15.4 million in Q1 2026, while quarterly EPS ranged between US$0.32 and US$0.44 before landing at US$0.11 in the latest period. This sets up a results season in which...

With attention fixed on whether heavy AI spending at Microsoft, Amazon, Meta, and Alphabet can keep driving the S&P 500, many investors are quietly asking where else to look if enthusiasm cools. One answer is to study how fresh earnings guidance and capex trends might redirect flows toward areas such as healthcare and financials. This article breaks down three large cap stocks from our Healthcare and Financials Rotation screener that are closely tied to these shifting expectations, helping...

Why the IDE892 trial update matters for IDEAYA Biosciences stock IDEAYA Biosciences (IDYA) has moved IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma. See our latest analysis for IDEAYA Biosciences. The IDE892 trial update lands at a time when IDEAYA Biosciences’ share price has shown firm momentum, with a 26.62% 90-day share price return and a 46.96% 1-year total...

Alamo Group stock has fallen 23.8% over the past year, and both its intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and its market multiples currently point to the shares trading at a discount to that intrinsic value. This raises a clear question about whether this weakness has gone too far. Alamo Group's share price decline of 23.8% over the last 12 months means investors are facing a recent loss, even as valuation tools now suggest the stock may be priced below its...

Extreme Networks (EXTR) has drawn attention after recent share price moves, with the stock last closing at $29.95. Investors are weighing this valuation against the company’s current revenue, earnings profile, and recent return history. See our latest analysis for Extreme Networks. Recent trading in Extreme Networks reflects a mix of cooling short term momentum and stronger longer term gains, with the 30 day share price return down 5.64% but the 90 day share price return up 75.66%, and the 1...

Q2 Earnings Highlight Lower Profitability For NVR NVR (NVR) reported second quarter 2026 results that showed net income of US$236.46 million, down from US$333.74 million a year earlier. Basic and diluted earnings per share also declined versus the prior period. See our latest analysis for NVR. NVR's share price has softened in recent months, with a 1 day share price return that declined 1.61%, a 30 day share price return that declined 7.57%, and a year to date share price return that declined...

Albertsons Companies (ACI) is back in focus after first quarter earnings showed net income of US$84.7 million on US$24,941.6 million in sales, alongside news that its President and Chief Financial Officer plans to retire. See our latest analysis for Albertsons Companies. The latest results and leadership change come after a difficult spell for Albertsons Companies, with the share price down 34.32% year to date and the 1 year total shareholder return declining 39.80%. This suggests momentum...

Zeta Global recently closed a new US$1.00 billion credit facility to refinance its prior US$550.00 million facility, lowering credit spreads and enhancing liquidity to support mergers and acquisitions, share repurchases, and general corporate purposes. By reducing its cost of capital while materially expanding available credit, Zeta Global has increased its financial room to fund growth initiatives without relying solely on equity. Next, we will examine how this larger, lower-cost credit...

The U.S. government’s seizure and sale of more than US$13b of Venezuelan oil in 2026 has injected fresh supply into global markets, stirred political debate in Washington, and put a spotlight on large U.S. energy companies. For investors, this mix of extra barrels, policy questions, and potential price volatility can create both openings and risks across the sector. This article walks through 3 stocks from the U.S. Energy Sector Stocks screener that are closely tied to this news, outlining...

Allergan Aesthetics, an AbbVie company, received European approval for Boey, a botulinum toxin serotype E injectable for glabellar lines. Boey is described as a first in its class in Europe, with rapid onset and short duration properties that differ from existing neurotoxin options. The launch expands AbbVie’s aesthetics portfolio, an important focus area for NYSE:ABBV following the loss of Humira exclusivity. For AbbVie, aesthetics sit alongside immunology and oncology as a core business...

Edible Garden AG Incorporated is expanding distribution of its fresh cut herbs with Walmart across the Mid-Atlantic region. The rollout focuses on sustainably produced, premium herbs supplied through controlled environment agriculture. The partnership broadens Walmart's domestic sourcing for fresh food and increases product variety in its grocery aisles. Walmart, NasdaqGS:WMT, enters this expanded herb partnership with Edible Garden at a time when its stock trades around $111.74 and has...

Lam Research has delivered a very strong 5 year run, yet its recent slump and a low overall value score suggest the stock is no straightforward bargain at US$291.61. The share price has returned about 3.8x over 5 years, which puts extra focus on whether current expectations already bake in much of the story. Recent enthusiasm around AI driven semiconductor equipment spending and Lam Research's role in chip manufacturing tools can support sentiment, while concerns about higher capital...

Agios Pharmaceuticals recently reported topline Phase 2 results for tebapivat in sickle cell disease and, citing insufficient differentiation versus other pyruvate kinase activators, decided to halt further development in this indication despite observing hemoglobin and hemolysis improvements and a safety profile aligned with prior trials. At the same time, the company is pursuing an alternative path in sickle cell disease through the FDA’s Priority Review of a supplemental New Drug...

In recent months, Lucid Group has come under growing scrutiny as mounting losses, very large negative gross margins, shrinking cash reserves, and leadership changes have fueled speculation about its financial stability and even potential bankruptcy risk. This pressure contrasts sharply with earlier optimism around its autonomous-vehicle partnerships and technology roadmap, highlighting how quickly confidence can shift when balance sheet strength and cash burn become central concerns. We’ll...

In July 2026, BigBear.ai expanded its generative AI platform for Department of War mission teams, adding air-gapped hardware, flexible tenant configurations, and both cloud-connected and fully local deployment options up to Top Secret/SCI classification. A key shift is the move to a refactored, model-agnostic platform with white-label, bring-your-own-model procurement choices, while phasing out the Ask Sage brand for Department of War users. Next, we’ll examine how the new air-gapped,...

Clean Harbors (CLH) is in focus after the company named long-time director Robert Willett as Chairman of the Board, following founder Alan S. McKim’s retirement from the board after more than four decades. See our latest analysis for Clean Harbors. Clean Harbors’ latest share price of $301.75 sits against a mixed recent pattern, with the share price declining over the past week but supported by a strong year to date share price return of 23.95% and a 5 year total shareholder return of...

Chinese manufacturers are rapidly expanding capacity in commodity NAND and DRAM, directly overlapping with NasdaqGS:SNDK core product areas. China is pushing ahead with domestic chip-making machinery, which may reduce reliance on foreign equipment suppliers. Regulatory and policy moves in China are creating roadblocks for international chip companies operating in the country. These developments introduce new competitive and supply chain risks for Sandisk that have not been fully discussed in...

Pagaya Technologies (PGY) recently closed an upsized, AAA-rated US$900 million personal loan ABS deal under its PAID 2026-5 program, a financing milestone supported by record year-to-date issuance volumes. See our latest analysis for Pagaya Technologies. The latest ABS milestone comes as Pagaya Technologies’ share price has climbed 25.91% over the past 90 days but remains down 23.88% year to date, with a 1 year total shareholder return that has declined 45.45%. This points to improving short...

Albemarle stock has rebounded strongly over the past year, yet the latest valuation checks and an overvalued read on market multiples leave investors weighing whether the recent price strength still leaves enough compensation for the risks. Albemarle has delivered a 57.5% return over the last year, which puts recent weakness into context and raises the question of how much of the recovery is already reflected in the share price. The long term cesium offtake agreement tied to the Case Lake...

In July 2026, Alnylam Pharmaceuticals reported past progress on its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference, including initiating the Phase 2 APPlauDS trial of mivelsiran in Down syndrome-associated Alzheimer’s disease, completing enrollment in the Phase 2 cAPPricorn-1 study in cerebral amyloid angiopathy, and advancing ALN-5288 into a first-in-human trial with Regeneron. Early mivelsiran data in Alzheimer’s disease showed sustained biomarker...

Why World Kinect’s latest earnings are moving the stock World Kinect (WKC) is back on investors’ radar after reporting a shift to net income in the second quarter, record adjusted earnings, higher gross profits and a lift to full year guidance. See our latest analysis for World Kinect. The earnings surprise and updated guidance appear to be feeding into strong momentum for World Kinect, with a 30 day share price return of 18.00% and a 90 day share price return of 48.30%. Over the longer term,...

ExxonMobil Holdings has delivered a very strong 223.0% return over the past 5 years, yet current checks suggest the stock may still trade below an intrinsic value estimate built from a Discounted Cash Flow (DCF) model and supported by earnings based multiples. That combination puts the focus on whether the recent strength in ExxonMobil’s share price has fully reflected the cash flows investors expect from its oil and gas business. A 223.0% 5 year return signals that ExxonMobil has already...

AI hardware stocks have just taken a hit, with NVIDIA, AMD and Dell all under pressure as investors question how much of the current AI buildout is backed by supplier financing rather than organic demand. That kind of broad risk-off move can create pricing dislocations, especially for large, diversified tech platforms that are only partially exposed to the AI cycle. This article walks through 3 stocks from our Large-Cap Diversified Tech Platforms screener that are closely tied to the latest...